One Test, 7,000+ Suspects: Hunting Down Hidden Infections with PanPathogen NGS

by Posted on

A fever that won’t break. Cultures that stay negative. A patient on antibiotics nobody can name a target for. What if one test could check for 7,000+ culprits at once?

The Silent Pandemic We’re Already Living In

Infections aren’t a solved problem. They’re getting harder. Sepsis, the body’s extreme response to infection, is linked to about 1 in 5 deaths worldwide. Germs are also learning to survive our drugs: antimicrobial resistance (AMR) directly killed 1.14 million people in 2021 and is forecast to cause 39 million+ deaths between 2025 and 2050.

The best weapon against both is speed: knowing exactly what you’re fighting before the infection, or the resistance, gets ahead.

When Cultures Stay Silent

Culture and PCR are brilliant at one question: is it this organism? They stumble when the real question is what on earth is it?

Culture needs the bug to grow. Slow growers may never show up, and antibiotics given before sampling can wipe out growth. PCR panels only find what they were built to find. Testing one suspect at a time costs days, and every day on the wrong drug adds risk.

Next-generation sequencing (NGS) flips the script. Instead of guessing, it reads the microbial DNA and RNA in a sample and reports what’s there: bacteria, viruses, fungi, and parasites in one run, with no culture needed.

One Assay. 7,000+ Suspects. Zero Guesswork.

The Genes2Me PanPathogen NGS Panel puts that power into a single, practical test. About 8,000 probes hunt for more than 7,000 organisms, covering bacteria, fungi, viruses, parasites, spirochetes and intracellular pathogens. The same run also screens 4,200+ drug-resistance genes.

It finds the usual suspects, like Staphylococcus aureus, Klebsiella, Candida and Aspergillus, and the elusive ones culture often misses, such as Nocardia, Rickettsia and Mycoplasma.

The real innovation is that G2M delivers the whole journey: library prep and capture reagents, compatibility with your existing sequencer, and CliSeq Interpreter software for the final report. One partner and one validated path, with no patchwork.

From Sample to Answer, End to End

Blood, sputum, BAL, CSF, swabs, tissue: almost any sample can go in. DNA and RNA are processed together, so RNA viruses aren’t missed. Wet-lab work fits into two working days, with an overnight capture in between.

PanPathogen end-to-end workflow · 7 steps

The Hybrid Capture Edge

Here’s the catch with most clinical samples: human DNA drowns out microbial DNA. Plain shotgun sequencing spends most of its reads on the patient.

PanPathogen fixes this with hybridization capture. Biotin-tagged probes latch onto pathogen sequences, and magnetic beads pull them out while the human background washes away. The probes target the regions that tell organisms apart (16S/18S rRNA, ITS and MLST housekeeping genes) plus resistance genes. The result is trace-level detection from just ~1 GB of data.

At a glance 
Organisms7,000+
Resistance genes4,200+ (CARD), risk-ranked I–IV
Limit of detection100–500 copies/mL
Reproducibility96–97%
On-target ratio>75%
Data per sample~1 GB

Any Sequencer. One Interpreter. A Report That Speaks.

Platform agnostic. PanPathogen kits run on Illumina, MGI, Element AVITI and Thermo Fisher platforms, in 48- and 96-test formats.

CliSeq Interpreter. Millions of reads mean nothing until someone makes sense of them. G2M’s CliSeq Interpreter does it automatically, on the cloud or on-site, with no coding required. It runs quality checks, classifies reads against curated databases (SILVA, Greengenes, RDP, UNITE) and maps resistance genes against CARD.

A detailed CSM report. The output is a clinically significant findings (CSM) report that a clinician can read in minutes:

  • every organism detected, with read counts and relative abundance
  • human background reported separately, so run quality is clear
  • resistance genes with mechanism, drug classes affected, likely host and risk level
  • a visual chart of the microbial mix, plus methodology and limitations

It’s honest, too. Sequencing can’t always tell a colonizer from a culprit, so results are designed to support clinical judgment, not replace it.

Ready to See What Others Miss?

Sepsis, meningitis, severe pneumonia, infections in transplant and cancer patients, hospital outbreaks: when the usual tests come up empty, PanPathogen keeps looking.

One assay. 7,000+ pathogens. 4,200+ resistance genes. One partner from sample to report.

Talk to the Genes2Me team to request a sample report or bring PanPathogen NGS to your lab.

PanPathogen NGS supports, and does not replace, clinical judgment. Results should be interpreted by a qualified clinician.

Published by Genes2Me

Established in 2016, Genes2Me is a leading molecular diagnostics company committed to transforming healthcare through innovative, high-quality in vitro diagnostic (IVD) solutions. Built on a strong foundation of scientific excellence and precision engineering, Genes2Me develops and manufactures advanced diagnostic technologies that enable accurate, reliable, and timely clinical decision-making across diverse healthcare settings worldwide. With a comprehensive and rapidly expanding portfolio, Genes2Me offers cutting-edge solutions across molecular diagnostics, including Next Generation Sequencing (NGS) clinical assays, point-of-care (POC) testing platforms, RT-PCR kits and instruments, as well as nucleic acid extraction kits and automation systems. Designed to meet the evolving needs of modern laboratories and clinicians, our products combine performance, scalability, and operational efficiency. A vast majority of Genes2Me products are CE-IVD marked, reflecting our commitment to global quality benchmarks, regulatory compliance, and uncompromising product standards. At the heart of our innovation are proprietary platforms such as OnePCR and Rapi-Q, developed to deliver rapid, multiplex, and highly sensitive molecular detection with streamlined workflows and minimal turnaround time. OnePCR integrates automated nucleic acid extraction and RT-PCR into a single, seamless workflow, enabling the detection of up to 20 targets from a single sample with exceptional precision and efficiency. The Rapi-Q series is engineered for fast, sensitive, and multiplex testing with a larger throughput, empowering healthcare providers with timely diagnostic insights that support improved patient outcomes. In genomics, Genes2Me offers one of the industry’s most comprehensive NGS clinical assay portfolios, spanning oncology, liquid biopsy, whole exome sequencing, NIPT and pharmacogenomics. Complementing this portfolio is EZY AutoPrep, our advanced automated library preparation workstation designed to optimize NGS library preparation through enhanced accuracy, reproducibility, and scalability. Our genomics ecosystem is further strengthened by CliSeq Interpreter, a cloud-based bioinformatics platform that enables accurate, flexible, and intuitive interpretation of complex genomic data, helping laboratories generate high-confidence insights with efficiency and ease. Driven by innovation, quality, and a global vision, Genes2Me continues to redefine the future of molecular diagnostics—delivering integrated solutions that advance precision medicine and improve lives worldwide.